These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 838805)

  • 21. Comparison of erythromycin base and estolate in gonococcal urethritis.
    Brown ST; Pedersen HB; Holmes KK
    JAMA; 1977 Sep; 238(13):1371-3. PubMed ID: 408522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of erythromycin estolate by liquid chromatography.
    Cachet T; Delrue M; Paesen J; Busson R; Roets E; Hoogmartens J
    J Pharm Biomed Anal; 1992; 10(10-12):851-60. PubMed ID: 1298393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group.
    Hoppe JE
    Pediatr Infect Dis J; 1992 Mar; 11(3):189-93. PubMed ID: 1565532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of oral suspensions containing sulfonamides in combination with erythromycin ethylsuccinate.
    Elrod L; Cox RD; Plasz AC
    J Pharm Sci; 1982 Feb; 71(2):161-6. PubMed ID: 6977637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 26. High-performance liquid chromatography of erythromycin propionyl ester and erythromycin base in biological fluids.
    Stubbs C; Kanfer I
    J Chromatogr; 1988 May; 427(1):93-101. PubMed ID: 3410906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems.
    Dujovne CA; Salhab AS
    Pharmacology; 1980; 20(6):285-91. PubMed ID: 7403251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatocellular jaundice due to erythromycin estolate].
    Zlotnick A
    Harefuah; 1978 Aug; 95(3-4):127-8. PubMed ID: 700498
    [No Abstract]   [Full Text] [Related]  

  • 29. Erythromycin propionate and estolate.
    Farre M
    Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
    [No Abstract]   [Full Text] [Related]  

  • 30. The pharmacokinetics and tolerance of oral erythromycin stearate compared with erythromycin ethylsuccinate: implications for preventing endocarditis.
    Shanson DC; Tidbury P; McNabb WR; Tadayon M
    J Antimicrob Chemother; 1984 Aug; 14(2):157-63. PubMed ID: 6334070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability in the absorption and disposition of erythromycin estolate in humans.
    Stubbs C; Kanfer I
    J Pharm Sci; 1989 Aug; 78(8):635-8. PubMed ID: 2778669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythromycin estolate hepatotoxicity.
    Lloyd-Still JD; Sherman JO; Boggs J; Demers LM
    Am J Dis Child; 1978 Mar; 132(3):320. PubMed ID: 629252
    [No Abstract]   [Full Text] [Related]  

  • 33. Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin.
    Tjandramaga TB; Van Hecken A; Mullie A; Verbesselt R; De Schepper PJ; Verbist L; Josefsson K
    Pharmacology; 1984; 29(6):305-11. PubMed ID: 6334320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of blood levels after oral administration of erythromycin and erythromycin estolate.
    GRIFFITH RS; BLACK HR
    Antibiot Chemother (Northfield); 1962 Jun; 12():398-403. PubMed ID: 13901859
    [No Abstract]   [Full Text] [Related]  

  • 35. [Determination of erythromycin estolate in pharmaceutical preparations containing tetracycline].
    Macioci F; Fiotek C
    Boll Chim Farm; 1973 Aug; 112(8):543-52. PubMed ID: 4770236
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 38. Erythromycin estolate for treatment of pertussis.
    Torre D; Maggiolo F; Quadrelli C; Sampietro C
    Pediatr Infect Dis; 1986; 5(6):719-20. PubMed ID: 3797311
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 40. [Component composition and admixtures of related compounds in commercial preparations with an erythromycin base].
    Zak AF; Batuashvili TA
    Antibiotiki; 1977 Nov; 22(11):970-4. PubMed ID: 596843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.